183 related articles for article (PubMed ID: 37496218)
1. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
Takakura T; Yamamoto N
Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
[TBL] [Abstract][Full Text] [Related]
2. Metastatic
Yun KM; Bazhenova L
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
[TBL] [Abstract][Full Text] [Related]
3. Consensus for HER2 alterations testing in non-small-cell lung cancer.
Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
[TBL] [Abstract][Full Text] [Related]
4. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233
[TBL] [Abstract][Full Text] [Related]
5. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
Riudavets M; Sullivan I; Abdayem P; Planchard D
ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
[TBL] [Abstract][Full Text] [Related]
6. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.
Yu Y; Yang Y; Li H; Fan Y
Cancer Treat Rev; 2023 Mar; 114():102520. PubMed ID: 36738637
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
He X; Hou L; Bai J; Sun C; Wang D; An G
Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
9. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Deruxtecan in
Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.
Neupane N; Thapa S; Bhattarai A; Ahuja K; Schlam I; Mittal A; Tolaney SM; Tarantino P
Curr Oncol Rep; 2023 Dec; 25(12):1467-1482. PubMed ID: 37938529
[TBL] [Abstract][Full Text] [Related]
14. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
[TBL] [Abstract][Full Text] [Related]
15. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
Jørgensen JT
Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
[TBL] [Abstract][Full Text] [Related]
16. Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).
Gaye E; Penel N; Lebellec L
Curr Opin Oncol; 2022 Sep; 34(5):570-574. PubMed ID: 35943440
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.
O'Rourke K
Cancer; 2022 Mar; 128(5):938. PubMed ID: 35147987
[No Abstract] [Full Text] [Related]
19. [Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy].
Rivier C; Lavaud P
Bull Cancer; 2024 Jun; 111(6):539-540. PubMed ID: 38553285
[No Abstract] [Full Text] [Related]
20. Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.
Wu HX; Zhuo KQ; Wang K
Br J Clin Pharmacol; 2022 May; 88(5):2019-2034. PubMed ID: 34820879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]